Leap Therapeutics Stock Performance
| LPTX Stock | USD 2.55 0.03 1.16% |
The company secures a Beta (Market Risk) of 1.05, which conveys a somewhat significant risk relative to the market. Leap Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Leap Therapeutics is expected to follow. At this point, Leap Therapeutics has a negative expected return of -0.0127%. Please make sure to verify Leap Therapeutics' total risk alpha, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Leap Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Leap Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Leap Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.58 | Five Day Return (8.63) | Year To Date Return (44.43) | Ten Year Return (96.70) | All Time Return (96.70) |
Last Split Factor 1:10 | Last Split Date 2023-06-21 |
1 | Acquisition by Cynthia Sirard of 5000 shares of Leap Therapeutics subject to Rule 16b-3 | 09/09/2024 |
2 | Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients | 09/30/2024 |
3 | Acquisition by Mashiach Nissim of 25000 shares of Leap Therapeutics at 2.45 subject to Rule 16b-3 | 10/02/2024 |
4 | Disposition of 50000 shares by Jason Baum of Leap Therapeutics at 2.57 subject to Rule 16b-3 | 10/10/2024 |
5 | Disposition of 2136 shares by Mirabelli Christopher of Leap Therapeutics at 2.82 subject to Rule 16b-3 | 11/13/2024 |
6 | Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. - MarketBeat | 11/15/2024 |
| Begin Period Cash Flow | 65.5 M |
Leap |
Leap Therapeutics Relative Risk vs. Return Landscape
If you would invest 280.00 in Leap Therapeutics on August 24, 2024 and sell it today you would lose (25.00) from holding Leap Therapeutics or give up 8.93% of portfolio value over 90 days. Leap Therapeutics is currently does not generate positive expected returns and assumes 5.272% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Leap, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Leap Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Leap Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Leap Therapeutics, and traders can use it to determine the average amount a Leap Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0024
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LPTX |
Estimated Market Risk
| 5.27 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Leap Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Leap Therapeutics by adding Leap Therapeutics to a well-diversified portfolio.
Leap Therapeutics Fundamentals Growth
Leap Stock prices reflect investors' perceptions of the future prospects and financial health of Leap Therapeutics, and Leap Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Leap Stock performance.
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 36.41 M | ||||
| Shares Outstanding | 38.32 M | ||||
| Price To Earning | (1.85) X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 160.10 X | ||||
| Gross Profit | 1.5 M | ||||
| EBITDA | (80.99 M) | ||||
| Net Income | (81.41 M) | ||||
| Cash And Equivalents | 90.88 M | ||||
| Cash Per Share | 0.92 X | ||||
| Total Debt | 262 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.88 X | ||||
| Book Value Per Share | 2.35 X | ||||
| Cash Flow From Operations | (43.75 M) | ||||
| Earnings Per Share | (1.64) X | ||||
| Market Capitalization | 98.86 M | ||||
| Total Asset | 72.83 M | ||||
| Retained Earnings | (399.58 M) | ||||
| Working Capital | 58.91 M | ||||
| Current Asset | 2.38 M | ||||
| Current Liabilities | 22.01 M | ||||
About Leap Therapeutics Performance
Evaluating Leap Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Leap Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Leap Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.12) | (1.17) | |
| Return On Capital Employed | (1.45) | (1.37) | |
| Return On Assets | (1.12) | (1.17) | |
| Return On Equity | (1.35) | (1.29) |
Things to note about Leap Therapeutics performance evaluation
Checking the ongoing alerts about Leap Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Leap Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Leap Therapeutics generated a negative expected return over the last 90 days | |
| Leap Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (81.41 M) with profit before overhead, payroll, taxes, and interest of 1.5 M. | |
| Leap Therapeutics currently holds about 90.88 M in cash with (43.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.92. | |
| Leap Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. - MarketBeat |
- Analyzing Leap Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Leap Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Leap Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Leap Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Leap Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Leap Therapeutics' stock. These opinions can provide insight into Leap Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.